A 42-kDa fragment from the C terminus of major merozoite surface protein 1 (MSP1) is among the leading malaria vaccine candidates that target infection by asexual erythrocytic-stage malaria parasites. The MSP1 42 gene fragment from the Vietnam-Oak Knoll (FVO) strain of Plasmodium falciparum was expressed as a soluble protein in Escherichia coli and purified according to good manufacturing practices. This clinical-grade recombinant protein retained some important elements of correct structure, as it was reactive with several functional, conformation-dependent monoclonal antibodies raised against P. falciparum malaria parasites, it induced antibodies (Abs) that were reactive to parasites in immunofluorescent Ab tests, and it induced strong growth and invasion inhibitory antisera in New Zealand White rabbits. The antigen quality was further evaluated by vaccinating Aotus nancymai monkeys and challenging them with homologous P. falciparum Plasmodium falciparum malaria afflicts more than 200 million people per year (41) and is estimated to kill one African child every 30 s (2). The development of vaccines against this disease is increasingly important due to the spread of multidrug-resistant malaria parasites.
Plasmodium falciparum malaria afflicts more than 200 million people per year (41) and is estimated to kill one African child every 30 s (2). The development of vaccines against this disease is increasingly important due to the spread of multidrug-resistant malaria parasites.
The major surface protein from merozoites (merozoite surface protein 1 [MSP1] ) is among the leading erythrocytic-stage candidates for inclusion in a multistage malaria vaccine. In P. falciparum, this protein ranges in size from 185 to 200 kDa and is attached at its C terminus to the parasite plasma membrane via a glycosylphosphatidylinositol anchor (15) . MSP1 is present on the merozoite's surface as a complex of fragments (25, 27) derived by proteolytic processing of the precursor (21, 22, 25) . During erythrocytic invasion by merozoites, MSP1 42 , which is the major fragment from the C terminus, is processed secondarily, producing a 33-kDa fragment (MSP1 33 ) from the N terminus and a 19-kDa fragment from the C terminus (MSP1 19 ). MSP1 19 is highly structured, folding into two epidermal growth factor (EGF)-like domains known as EGF-like domain 1 and EGF-like domain 2 (29) . MSP1 19 remains attached to the merozoite surface and is present on ring forms in newly invaded erythrocytes (4, 5) . Sequence variation among MSP1 42 molecules from different P. falciparum strains is primarily dimorphic (28) .
Both MSP1 42 and MSP1 19 are established targets of protective immunity in animal models, and in the case of the rodent malaria model, Plasmodium yoelii, the protection observed is strain specific (33) . Additional evidence for the importance of this region of MSP1 in immunity includes the observation that MSP1 19 -specific monoclonal antibodies (MAb) inhibit P. falciparum growth in vitro (3, 10) and passively protect mice against P. yoelii malaria infection (24, 26) . It has also been shown that MAbs that inhibit P. falciparum growth in vitro also inhibit the secondary processing of MSP1 42 (6) and bind to conformational epitopes that are lost when cystines are reduced. MSP1 19 -specific Abs have proven to be the major contributors to the invasion-inhibitory response in humans who are immune to malaria (30) , and double domain-specific p19 as well as EGF domain 2-specific antibodies affinity purified from human immune sera prevent parasite invasion in vitro (13) . Several studies have shown that rabbit antisera raised against recombinant MSP1 42 inhibit P. falciparum growth in vitro (1, 8, 35) .
The active vaccination of Aotus nancymai monkeys with Escherichia coli (35)-and baculovirus (7, 36, 37) -expressed recombinant P. falciparum MSP1 42 induces a significant homologous protective effect against infection by erythrocyticstage P. falciparum strain FVO. MSP1 42 purified from transgenic mouse milk also induces protection, but this result depends on removing two N-glycosylation sites from the protein (36) . Since P. falciparum does not N-glycosylate proteins, expression strategies that avoid glycosylation should be most suited for malaria vaccines based on MSP1 42 . E. coli offers this possibility, and two approaches can be taken. One is to allow E. coli to express and fold the protein such that it is either soluble or can be solubilized by the use of mild detergents (1) , and the other is to purify the protein from inclusion bodies and refold it in vitro (35) . The present work follows the first approach.
Our objective was to manufacture a clinical-grade E. coliexpressed recombinant MSP1 42 (FVO) antigen (Ag) that preserved various elements of the correct antigen structure, as evidenced by its binding of functional MAbs specific for conformation-dependent epitopes. Furthermore, we wanted to show that this Ag was capable of inducing functional immunity by using growth inhibition assays to evaluate vaccinated rabbit sera or by challenging vaccinated A. nancymai monkeys with the highly virulent FVO strain of P. falciparum, which is homologous to the vaccine. For the vaccination experiments, we chose to use Freund's adjuvant because, to date, it is the only adjuvant that has shown the capacity to induce protective immunity in the Aotus monkey model. Taking this approach allowed us firstly to determine if we met our objective of manufacturing efficacious clinical-grade FVO strain MSP1 42 , which has not been accomplished previously, and secondly to compare the performance of our antigen with those of several non-clinical-grade Ags that have already been evaluated. This comparison was facilitated by the use of baculovirus-expressed FVO strain MSP1 42 (37) , which has been compared with other MSP1 42 preparations (35) (36) (37) , as a positive control. Our clinical-grade E. coli-derived MSP1 42 induced a strong protective effect in Aotus monkeys, protecting all animals against uncontrolled parasitemia, while all animals in the negative control group, who were immunized with the 25-kDa sexual-stage antigen from Plasmodium vivax (Pvs25) (20) , were treated for uncontrolled parasitemia, as were two of five animals in the positive control group, who were vaccinated with baculovirusexpressed MSP1 42 . This soluble E. coli-expressed MSP1 42 (FVO) Ag is a strong prospect as a component of an erythrocytic-stage malaria vaccine.
MATERIALS AND METHODS

Construction of expression vector pET(AT)PfMSP1 42 (FVO).
Initial experiments showed that we could not express the wild-type MSP1 42 gene fragment (GenBank accession no. L20092) in E. coli in a quantity that was sufficient for purification. This problem was solved by introducing a synonymous mutation in codon 141 (Ile) at bp 423 (C3A) (numbered from the start of the native MSP1 42 sequence from L20092), permitting expression at the level of 0.05 mg/g of cell paste. The rationale for this mutation will be reported elsewhere (unpublished data). The mutation was introduced by PCR to generate two overlapping fragments of the MSP1 42 gene that were annealed and extended prior to PCR amplification to prepare the final product. The primers used to prepare the overlapping fragments were FVO-PCR1 (5Ј-GGGTCGGTACCATGGCAGTA ACTCCTTCCGTAATTGAT-3Ј), which was paired with EA5 (5Ј-AAAAGGG AAGGTATTTCTCATT-3Ј), and FVO-PCR2, (5ЈGGATCAGATGCGGCCGC TTAACTGCAGAAAATACCATCGAAAAGTGGA-3Ј), which was paired with EA3 (5Ј-TAAAAAATATATAAACGACAAAC-3Ј). The base change relative to the native sequence in primer EA3 is underlined.
The two products, FVO-PCR1/EA5 and EA3/FVO-PCR2, were purified by gel extraction with a QIAEX II kit. An equimolar mixture of the two oligonucleotides was then used in combination with the flanking primers FVO-PCR1 and FVO-PCR2 to produce a full MSP1 42 (FVO) gene fragment possessing NcoI and NotI restriction sites at the 5Ј and 3Ј ends, respectively.
Molecular cloning and bacterial transformations were performed as follows. The MSP1 42 (FVO) gene fragment and the expression vector pET(AT) PfMSP1 42 (3D7) (1) were digested with NcoI and NotI and purified by extraction from agarose gels (QIAEX II; Qiagen, Chatsworth, Calif.). The DNAs were ligated with T4 DNA ligase (Roche Diagnostics Corporation, Indianapolis, Ind.), producing the plasmid pET(AT)PfMSP1 42 (FVO), which was used to transform
(Invitrogen, Carlsbad, Calif.) to tetracycline resistance (Boehringer Mannheim, Indianapolis, Ind.). The MSP1 42 insert was fused N-terminally to 17 non-MSP1 amino acids that included an N-terminal hexahistidine tag (Fig. 1) .
GMP fermentation and expression. Based on conditions obtained from laboratory scale 10-liter fermentations, a 300-liter good manufacturing practices (GMP) fermentor containing Super Broth medium supplemented with 15 g of tetracycline/ml was inoculated with 3 liters of fresh stationary-phase culture in accordance with batch production record (BPR) 444-00. Fermentation continued at 37°C to an optical density at 600 nm (OD 600 ) of 4.5. The culture temperature was reduced from 37 to 25°C prior to the induction of protein expression with 0.1 mM IPTG (isopropyl-␤-D-thiogalactopyranoside) for 2.5 h. At the end of the induction, the cells were harvested by use of a Sharples AS-26 centrifuge at 27,666 ϫ g at a rate of 3 liters/min, and the E. coli cell paste was stored at Ϫ80°C at the Pilot Bioproduction Facility, Department of Biologics Research, Walter Reed Army Institute of Research (WRAIR), Silver Spring, Md.
GMP purification of BPR 444-00, lot no. 0792. The cell paste (2.8 kg) was lysed in buffer (8.4 liters) containing 10 mM sodium phosphate (pH 6.2), 50 mM sodium chloride, 80 mM imidazole, 2 mM magnesium chloride, and 50 U of benzonase/ml. After cell lysis by microfluidization, Tween 80 (NOF Corporation, Hyogo, Japan) and sodium chloride were added to final concentrations of 1.0% (vol/vol) and 1.0 M, respectively, and the lysate was incubated on ice for 30 min with stirring prior to centrifugation at 27,666 ϫ g for 1 h at 4°C. The clarified lysate was collected and filtered through 0.45-m-pore-size filters (Millipore Corp., Bedford, Mass.). All subsequent steps were carried out at 4°C. Two chromatographic steps were used to purify the MSP1 42 (FVO) Ag to homogeneity.
For Ni 2ϩ -nitrilotriacetic acid Superflow (Qiagen) chromatography, a 230-ml column (12:1 [wt/vol] cell paste-to-resin ratio) was equilibrated with a solution containing 10 mM sodium chloride (pH 6.2), 1.0 M sodium chloride, 80 mM imidazole (Ni buffer), and 1.0% (vol/vol) Tween 80 (NOF Corporation). The column was loaded at a flow rate of 32 ml/min and washed with 20 column volumes of Ni buffer containing 1.0% Tween 80. The column was washed with 20 volumes of buffer containing 10 mM sodium phosphate (pH 6.2), 0.5 M sodium chloride, 80 mM imidazole, and 1.0% (vol/vol) Tween 80 followed by 20 volumes of buffer containing 10 mM sodium phosphate (pH 8.5), 75 mM sodium chloride, and 20 mM imidazole. MSP1 42 (FVO) was eluted by applying 5 column volumes of buffer containing 10 mM sodium phosphate (pH 8.5), 75 mM sodium chloride, 1 M imidazole, and 0.2% Tween 80 to the column.
For Q Sepharose chromatography, a Q Sepharose Fast Flow column (Amersham-Pharmacia Biotech, Piscataway, N.J.) (cell paste-to-resin ratio of 5:1 [wt/ vol]) was equilibrated with buffer containing 10 mM glycine (pH 9.6), 35 mM sodium chloride, 2 mM EDTA, and 0.2% Tween 80 (Q buffer). The eluate from the Ni chromatography step was diluted with an equal volume of buffer contain-ing 10 mM glycine (pH 9.6), 4 mM EDTA, and 0.2% Tween 80, and the pH was adjusted to 9.6 by the addition of 1 N sodium hydroxide. The column was loaded at a flow rate of 65 ml/min and then washed with 5 column volumes of Q buffer. The column was washed with 30 column volumes of wash buffer containing 10 mM glycine (pH 9.6), 0.1 M sodium chloride, 2 mM EDTA, and 0.2% Tween 80 at a flow rate of 82 ml/min, and the protein was eluted with 3 column volumes of buffer containing 10 mM sodium phosphate (pH 7.2), 0.2 M sodium chloride, 2 mM EDTA, and 0.2% Tween 80. The buffer was exchanged with a solution containing 1.7 mM potassium phosphate (monobasic), 5 mM sodium phosphate (dibasic), 0.15 M sodium chloride, and 0.1% Tween 80 (pH 7.1) by ultrafiltration with a UFP-3C-6A filter (molecular weight cutoff, 3,000; A/G Technology, Needham, Mass.), and the protein was concentrated to 0.5 mg/ml. The retentate was filter sterilized by use of a Millipak 60 0.22-m-pore-size filtration unit, and the final purified bulk was stored at Ϫ80°C.
SDS-PAGE and immunoblotting. The protein was analyzed by Tris-glycine SDS-PAGE under nonreducing or reducing (10% 2-mercaptoethanol) conditions followed by Coomassie brilliant blue R-250 (Bio-Rad Laboratories, Hercules, Calif.) staining or immunoblotting as previously described (1 GST fusion protein expression plasmids and protein expression. Glutathione S-transferase (GST)-EGF domain 1 (FVO), GST-EGF domain 2 (FVO), and GST-MSP1 19 (FVO) expression plasmids were constructed previously (10) and were used to transform E. coli BL21 DE3 to ampicillin resistance. Terrific Broth (Difco/Becton-Dickinson, Sparks, Md.) was inoculated with a 1/100 volume of fresh stationary-phase culture. The culture was grown at 37°C to an OD 600 of 0.6, cooled to 25°C, induced by the addition of 0.1 mM IPTG (final concentration), and cultured for an additional 2 h. The cells were collected by centrifugation at 6,000 ϫ g for 15 min, and the cell paste was stored frozen at Ϫ70°C.
GST fusion protein purification. The cell paste was suspended in lysis buffer (ice cold PBS-0.01 M dithiothreitol) at a paste-to-buffer ratio of 1:3 (wt/vol). Next, the cells were lysed by microfluidization in one pass; Triton X-100 (final concentration, 1% [vol/vol]), MgCl 2 (final concentration, 0.01 M), and DNase I (final concentration, 100 g/ml) were added; and the sample was incubated on ice for 30 min. The lysate was clarified by centrifugation at 27,666 ϫ g for 1 h at 4°C. The supernatant was collected and chromatographed on a 1-ml column of glutathione-Sepharose beads (Pharmacia) equilibrated with PBS-10 mM dithiothreitol-1% Triton X-100 (equilibration buffer). The loaded column was washed with 20 column volumes of equilibration buffer, and the fusion protein was eluted with 0.005 M reduced glutathione-0.05 M Tris-HCl, pH 8.0. The sample was stored at 0 to 4°C for 2 days to allow cystine formation and was then stored at Ϫ70°C. The protein concentration was quantified by the use of Folin Ciocalteau reagent (Lowry), and its purity was evaluated by SDS-PAGE under reducing and nonreducing conditions. The purified protein structure was evaluated by reac- ELISAs. Microtiter plate (Immulon-2 HB; Thermo Labsystems, Franklin, Mass.) wells were coated with 0.4 pmol of recombinant antigen in 50 l of PBS and then incubated overnight at 4°C. The plates were blocked for 1 h at room temperature with 150 l of blocking buffer (1% fraction V bovine serum albumin in PBS). Sera (primary antibodies) were diluted serially with blocking buffer, and the primary antibodies (50 l) were incubated for 1 h at room temperature. The plates were washed four times with wash buffer (0.05% Tween 20 and 0.0025% chlorohexidine in 1ϫ PBS) by use of a microplate washer (SkanWasher 300 version B; Skatron Instruments, Sterling, Va.). For measurements of Aotus monkey Ab responses, a goat anti-A. nancymai IgG heavy-plus-light chain peroxidase-labeled conjugate was diluted 1:8,000 in blocking buffer and added to plates at 50 l/well. The plates were incubated for 1 h at room temperature, washed, and developed by the addition of 100 l of the ABTS peroxidase substrate system (KPL, Gaithersburg, Md.) to each well. The absorbance at 405 nm of each well was measured after 30 min by use of a microplate reader (EL 312e automated microplate reader; Bio-tek Instruments, Inc., Winooski, Vt.). The midpoint antibody titer was calculated as the serum dilution that produced an absorbance of 1.0 optical density unit in the ELISA assay. Rabbit antibodies were measured in the same manner, except that the conjugate was goat antirabbit IgG Fc-alkaline phosphatase diluted to 1:1,000 (Promega, Madison, Wis.) and the substrate was p-nitrophenyl phosphate (Sigma), the product of which was measured at 405 nm.
For analyses comparing MSP1 42 fragment-specific Ab titers, the plate antigens were normalized to one another. Equimolar coatings (0.4 pmol/well) of each ELISA plate antigen were confirmed by detection with an antibody against the GST moiety of the fusion protein (in the case of p19, EGF1, and EGF2) or against MAb 5.2 (in the case of MSP1 42 and p19).
Rabbit immunization and inhibition of parasite growth and invasion. New Zealand White rabbits were immunized four times at 3-week intervals. They were primed with 200 g of E. coli-expressed MSP1 42 (FVO) in Freund's complete adjuvant (FCA) and boosted with 50 g of Ag in incomplete Freund's adjuvant (IFA). Sera were collected prior to immunization and 3 weeks after the last immunization and were adsorbed with type A human erythrocytes (18) .
Sera were evaluated for their inhibition of malaria parasite invasion and growth by measurements of lactate dehydrogenase levels in late trophozoitestage P. falciparum parasites by a protocol (C. A. Long, personal communication) adapted from a previously developed method (31) . P. falciparum strains 3D7 and FVO were synchronized by thermal cycling as described previously (17) and were collected for use at the beginning of schizogony. Cultures were adjusted to 0.3% parasitemia with type A human erythrocytes, and assays were conducted at a final hematocrit of 1%, with test serum concentrations ranging from 5 to 20%. Samples with P. falciparum 3D7 and FVO were collected 40 and 46 h, respectively, after initiation. Inhibition was calculated as follows: % inhibition ϭ [(OD immune serum Ϫ OD RBC ) Ϭ (OD preimmune serum Ϫ OD RBC )] ϫ 100.
Immune sera from rabbits that were vaccinated with an irrelevant Ag in Freund's adjuvant (with the same regimen as that for MSP1 42 ) and preimmune or normal rabbit sera were used interchangeably as negative control samples in this assay.
A. nancymai vaccination. The monkeys used for this study were A. nancymai monkeys of either sex with intact spleens and with no history of Plasmodium species infections, as determined by parasitological and serological examinations; they were in good health and free of tuberculosis. The monkeys weighed no less than 700 g at the start of the study and were stratified into groups of six animals according to weight and sex. Groups were then assigned randomly to the vaccine and control groups. Six monkeys were assigned per group.
Animals were vaccinated twice with 50 g of E. coli-expressed MSP1 42 , baculovirus-expressed MSP1 42 (37) , or recombinant Saccharomyces cerevisiae Pvs25 (20) emulsified in 0.5 ml of FCA or IFA (Difco Laboratories, Irvine, Calif.) for the first and second immunizations, respectively. The hair was closely shaved from the back region of the monkeys to allow visualization of any reactions, and four 125-l subcutaneous inoculations were given. Immunizations were given 7 weeks apart, and the animals were challenged 7 weeks after the last immunization.
All Aotus monkeys enrolled at the start of this study were healthy, but two animals, one of which was assigned to the Pvs25 control group and one of which was assigned to the baculovirus MSP1 42 group, died prior to challenge from complications unrelated to immunization.
A. nancymai challenge. The P. falciparum Vietnam Oak Knoll (FVO) strain is adapted to A. nancymai and produces a rapid, reproducible, lethal, high-density parasitemia in naïve monkeys with intact spleens. For challenge experiments, parasitized erythrocytes from a donor monkey were diluted to 20,000 parasitized red blood cells (PRBC)/ml in sterile RPMI 1640 tissue culture medium, and 0.5 ml was administered intravenously via the femoral vein.
Beginning 3 days after the challenge, Giemsa-stained blood smears were made to quantify the numbers of parasites per microliter of blood (12) . When parasite counts exceeded 80,000/l of blood, parasite densities were quantified from thin blood smears. Daily blood smears were prepared and evaluated for 56 days after the challenge. Monkeys that developed high-density parasitemia (Ͼ200,000 parasites/l of blood) were treated with mefloquine (Roche Laboratories, Nutley, N.J.) and quinine (Marion Merrel Dow, Inc., Kansas City, Kans.). Animals that developed anemia were cured with drugs and treated by iron supplementation and transfusion of whole blood if the hematocrit fell below 20%. Iron supplementation is a standard practice by veterinary staff for the treatment of malariainduced anemia; it helps to speed recovery and blood replacement in severely anemic animals.
Statistical analysis. (i) Rabbits. Data groups for vaccinated rabbits satisfied the criteria of equal variance and normality after natural logarithm transformation to stabilize variance (Box Cox; Minitab) and were further evaluated by analysis of variance to discern if differences existed among the various groupings of data; differences were then isolated by Tukey's posttest. Correlations between ELISA Ab titers and parasite inhibition were established by Pearson's regression analysis.
(ii) Aotus monkeys. The data from the Aotus trial did not satisfy the criteria of equal variance after transformation, and thus the results were evaluated by nonparametric methods. For the Aotus vaccine trial, the primary end point was the cumulative day 11 parasitemia, which was the summation of an individual animal's daily levels of parasitemia from the day of challenge until the 11th day after challenge. The 11th day after challenge was the day prior to treatment of the first animal for uncontrolled parasitemia. Day 11 parasitemia levels were ranked as shown in Table 1 , and end points for experimental groups were compared first by using Kruskal-Wallis tests to determine if any of the treatment groups had different primary end points. If a difference was discovered, it was isolated by secondary pairwise comparisons by use of the Mann-Whitney test. In addition to cumulative day 11 parasitemia as the primary end point, the day of patency was evaluated as a secondary end point. The relationships between the primary day 11 end point and Ab titers were evaluated by Spearman's regression analysis. 
RESULTS
Cloning. The MSP1 42 (FVO) gene fragment was prepared from the P. falciparum FVO genomic DNA by PCR in several steps (Fig. 1B) to introduce a synonymous codon by mutating nucleotide 423 (C to A) within codon 141. The PCR fragment was subcloned into the expression vector pET(AT)PfMSP1 42 (3D7) (Fig. 1A) . The final construct (Fig. 1C) Expression and purification. The expression of soluble MSP1 42 was induced with IPTG, and the protein was purified under GMP conditions by a two-step chromatographic method that included a Ni 2ϩ -nitrilotriacetic acid-Sepharose affinity resin followed by a Q-Fast Flow Sepharose ion exchanger. The final protein purity was Ͼ95% according to SDS-PAGE and Coomassie blue staining ( Fig. 2A and E) . This result was supported by the observations that no contaminating E. coli proteins were observed in Western blots probed with polyclonal rabbit anti-E. coli antibodies (data not shown) and that a 50-g dose of vaccine contained Ͻ2 ng of contaminating E. coli host protein, as measured by an ELISA for host protein quantification (data not shown). In addition, a 50-g dose of vaccine contained 60 endotoxin units (EU), well below the FDA's acceptable limits (350 EU/70 kg of human body weight). The residual Ni 2ϩ content remaining after purification was Ͻ2 g/g of MSP1 42 (FVO) according to ICP-OES.
Antigen characterization. Coomassie blue staining of SDS-PAGE gels revealed a doublet at 42 kDa, a 30-kDa proteolytic fragment, and some high-molecular-weight aggregates under nonreducing conditions (Fig. 2A, lane 2) . A single major monomer that migrated at approximately 50 kDa and minor components at 90 and 30 kDa (Fig. 2E, lane 2) were present after electrophoresis under reducing conditions.
Western blots probed with either polyclonal mouse anti-MSP1 42 (FVO) or rabbit anti-E. coli antibodies revealed that all Coomassie blue-detectable bands originated from MSP1 42 (data not shown). The N-terminal sequence of the 30-kDa fragment corresponded to the N terminus of MSP1 42 , indicating that this fragment is truncated at the C terminus of MSP1 42 .
The final bulk product (Fig. 2, lanes 2) was characterized structurally by immunoblotting and probing with various MSP1 19 -specific MAbs that react with conformational epitopes. MAbs 12.10 ( Fig. 2B and F Fig. 2D and E) ; the epitope recognized by MAb 5.2 reforms more readily under these conditions than the epitopes recognized by the other MAbs. The reactivity with MAb 5.2 observed under reducing conditions could be completely eliminated by reducing and alkylating the Ag (data not shown).
Rabbit immunization. The induction of antibodies was measured by ELISAs with the following capture antigens, which were homologous to the FVO vaccine strain: full-length E. coli MSP1 42 , C-terminal MSP1 19 (p19), EGF-like domain 1 (EGF1), and EGF-like domain 2 (EGF2). Fragment-specific Ab titers induced by the E. coli MSP1 42 (FVO) vaccine were ranked as follows: MSP1 42 Ͼ p19 ϭ EGF1 Ͼ EGF2 (Fig. 3A) . The E. coli MSP1 42 (FVO) vaccine induced two times more MSP1 42 -specific Ab than p19-specific Ab and about five times more MSP1 42 -specific Ab than EGF1-specific Ab, suggesting that most of the Ab induced was specific to conformational epitopes associated with the whole MSP1 42 antigen but not its fragments. The Ab titer against EGF2 was about 50-fold lower than the titer against MSP1 42 .
The immune rabbit sera had potent in vitro growth and invasion inhibitory activities against both the homologous FVO parasite and the heterologous 3D7 parasite (Fig. 3B) , although the activity against the FVO parasite was significantly stronger at all three serum dilutions tested (Student's t test; P Յ 0.024). Inhibition with 20% serum was not significantly higher than inhibition with 10% serum when tested against either the FVO or 3D7 parasite. The strongest correlation between ELISA Ab titers and growth and invasion inhibition was observed for the EGF2-specific Ab and inhibition of the FVO parasite with 20% serum (Pearson's R ϭ Ϫ0.784; P ϭ 0.021).
Aotus vaccination and challenge. Seven weeks after the second immunization, the monkeys were challenged with 10,000 P. falciparum strain FVO PRBC. By the 15th day after challenge, all monkeys in the control group had been treated for uncontrolled acutely rising parasitemia. In contrast, no animals in either of the MSP1 42 -vaccinated groups required treatment by this time (Fig. 4) . All six animals that were vaccinated with E. coli MSP1 42 began resolving their infections spontaneously at relatively low levels of parasitemia; two of these animals were subsequently treated for anemia (days 26 and 28), and none were treated for uncontrolled infection. Between the 19th and 28th day after challenge, four of the five monkeys that were vaccinated with baculovirus MSP1 42 were treated for either anemia (days 26 and 28) or uncontrolled parasitemia (days 19 and 23). One animal from this group self-cured its infection (Table 1 ). An evaluation of the primary end point, cumulative day 11 parasitemia, showed that at least one group among the three in the trial differed significantly from the other two (P ϭ 0.002 by Kruskal-Wallis test, both unadjusted and adjusted for ties). Pairwise isolation of the differences by the use of Mann-Whitney tests showed that both of the MSP1 42 -vaccinated groups had lower cumulative day 11 parasitemia levels than the Pvs25 control group (for E. coli MSP1 42 , P ϭ 0.0081; for baculovirus MSP1 42 , P ϭ 0.0122). The two MSP1 42 -vaccinated groups also differed from one another (P ϭ 0.0225), with the E. coli MSP1 42 -vaccinated group being the better protected of the two. An evaluation of the secondary end point, the day of patency, by the same process produced slightly different results (P ϭ 0.005 by Kruskal-Wallis test; P ϭ 0.003 when adjusted for ties). The isolation of these differences by use of a MannWhitney test showed that the E. coli MSP1 42 -vaccinated group differed from the Pvs25 control group (P ϭ 0.0081) but that the baculovirus MSP1 42 -vaccinated group did not (P ϭ 1). The days of patency for the E. coli MSP1 42 and baculovirus MSP1 42 groups also differed from one another (P ϭ 0.0081). Thus, E. coli MSP1 42 was significantly more efficacious than baculovirus MSP1 42 , as measured by differences in both the day 11 primary end points and the day of patency secondary end points.
Aotus serology and immune correlates. The induction of antibodies was measured by ELISAs with the same Ag set as that described for rabbits. The kinetics of Ab induction by these fragments were measured with pooled sera (Fig. 5) . A linear regression analysis of four contiguous points from the central parts of the kinetic plots (R 2 Ͼ 0.91 in all cases) showed that the rate of induction of MSP1 42 -specific Ab by E. coli MSP1 42 exceeded that by baculovirus MSP1 42 1.4-fold for EGF1, 2.5-fold for MSP1 42 and p19, and 6.5-fold for EGF2. For both groups of vaccines, the MSP1 42 -and EGF1-specific Abs began to plateau 3 weeks after the second immunization, but the p19-and EGF2-specific Ab titers did not reach a plateau even by the day of challenge, which was 7 weeks after the second immunization.
On the day of parasite challenge, fragment-specific Ab titers induced by both MSP1 42 vaccines ranked as follows: MSP1 42 Ͼ p19 ϭ EGF1 Ͼ EGF2 (Fig. 6 ). Both MSP1 42 vaccines induced four times more MSP1 42 -specific Ab than p19-specific Ab and about five times more MSP1 42 -specific Ab than EGF1-specific Ab, suggesting that, like the case for the rabbits, most of the Ab induced was specific to conformational epitopes associated with the whole MSP1 42 antigen. The Ab titer against EGF2 was about 50-fold lower than the titer against MSP1 42 , and the titer specific for the p33 product from the N terminus of MSP1 42 was the same as that observed for EGF2 (data not shown). When compared with baculovirus MSP1 42 , E. coli MSP1 42 induced significantly more MSP1 42 -specific (2.6-fold), p19-specific (2.7-fold), EGF1-specific (3.7-fold), and EGF2-specific (8.8-fold) Ab (P ϭ 0.006 by Kruskal-Wallis test for all responses). Antisera taken on the day of parasite challenge from the two groups of vaccines were also tested by a fluorescent antibody test (FAT) with P. falciparum FVO (data not shown). The results of the FAT provide additional evidence supporting the difference in the immunogenicity of the two Ags, as the FAT Ab titers for the E. coli Ag vaccinees were eightfold higher than those for the baculovirus Ag vaccinees. The day-of-challenge antisera were also tested by ELISAs, with both E. coli MSP1 42 and baculovirus MSP1 42 as capture Ags (data not shown). When the capture Ag was the E. coli MSP1 42 Ag, the ratio of mean Ab titer for the E. coli Ag vaccinees to that for the baculovirus Ag vaccinees was 2.6, while this ratio was 2.4 when the baculovirus MSP1 42 Ag was used. Thus, the choice of capture Ag for the ELISA analysis did not affect the interpretation of the results. Figure 7 shows Spearman's correlations between the various serologic responses measured for Fig. 6 and the primary end point. The p19-specific and EGF2-specific Ab titers induced by E. coli MSP1 42 -FCA correlated strongly with protection (R ϭ Ϫ0.9856 and Ϫ0.9276, respectively). None of the Ab responses induced by baculovirus MSP1 42 correlated with the primary end point that was used to define protection.
DISCUSSION
Several approaches to developing recombinant protein vaccines based on the MSP1 42 gene fragment from P. falciparum have been reported. Three constructs have been expressed in E. coli (1, 23, 35) , two have been expressed in baculovirus (8, 37) , and one has been expressed in transgenic mice (36) .
Results from various preclinical studies in which A. nancymai monkeys vaccinated with the FVO allele of MSP1 42 were challenged with the homologous strain of P. falciparum (23, (35) (36) (37) led Singh et al. to conclude that the protein expressed in E. coli performed at least as well as that expressed in baculovirus and that it offers the best prospect as a vaccine candidate owing to more favorable manufacturing issues (35) . There are two leading approaches for purifying the MSP1 42 protein expressed in E. coli, either cytoplasmic expression as a soluble protein (1) or extraction from inclusion bodies and refolding in vitro (35) . The present work took the former approach, and we described here the manufacture and characterization of clinical-grade P. falciparum MSP1 42 (FVO) expressed in a soluble form in E. coli and the testing of this Ag for efficacy in Aotus monkeys challenged with a homologous strain of erythrocytic-stage malaria parasites.
Our soluble E. coli MSP1 42 product met all FDA standards for purity and safety which are required for clinical testing. The measured residual endotoxin levels were significantly below the FDA's acceptable limits (FDA limit, 350 EU/dose/70 kg of human body weight; this product, 60 EU/dose/70 kg), and E. coli host proteins were below the limits of detection by ELISA. The product is comprised predominantly of full-length MSP1 42 and a minor portion of truncated MSP1 30 derived from the N terminus (confirmed by N-terminal amino acid sequencing) as (Fig. 2) . Additional evidence of the correct structure includes the induction of IFAreactive Abs, the induction of rabbit Abs that inhibit parasite growth and development in vitro, and the induction of protective immunity in A. nancymai.
Both the E. coli MSP1 42 vaccine and the baculovirus MSP1 42 control vaccine elicited protective host responses against homologous challenge. By day 15, all monkeys in the Pvs25-vaccinated negative control group, but none in either MSP1 42 group, had been treated for uncontrolled parasitemia. A comparison of differences in the end points of the treatment groups by Kruskal-Wallis analysis, followed by Mann-Whitney tests to isolate the differences, showed that the E. coli MSP1 42 vaccine was significantly more protective than the baculovirus MSP1 42 vaccine for cumulative day 11 parasitemia (P ϭ 0.0225) and the day of patency end point (P ϭ 0.0081).
The difference in the protective effects of the E. coli MSP1 42 and baculovirus MSP1 42 vaccines might be due to differences in the quantity and fine specificities of Ab that they induced. On the day of challenge with live parasites, Ab titers induced by the E. coli MSP1 42 vaccine were substantially higher than those induced by the baculovirus MSP1 42 vaccine, varying from 2.6 to 8.8 times higher according to the domain specificity of the Abs (Fig. 6 ). E. coli MSP1 42 induced C-terminal p19 fragment-and EGF-like domain 2-specific Ab responses that correlated strongly with protection in vivo (Spearman's R ϭ Ϫ0.9856 and Ϫ0.9267, respectively), but the responses induced against EGF-like domain 1 and full-length MSP1 42 did not correlate with protection (Spearman's R ϭ 0.5218 and 0.6377, respectively). These results are consistent with those of Guevara-Patino et al. (14) , who showed that an Ab to EGF-like domain 1 can block the activity of functional growth inhibitory Abs, and of Egan et al. (13) , who showed that human IgG affinity purified from protective immunoglobulin by the use of EGF-like domain 2 inhibits parasite growth in vitro, as does double-domain p19-specific IgG depleted of its EGF1 and EGF2 specificities. None of the Abs induced by the baculovirus MSP1 42 vaccine correlated with protection in vivo. It may also be relevant that a reasonably strong negative correlation was observed between EGF2-specific Ab titers induced by vaccinating rabbits with MSP1 42 (FVO) and the growth and invasion inhibition of P. falciparum FVO by those sera in vitro (Pearson's R ϭ Ϫ0.784; P ϭ 0.024). The strong growth inhibitory effect of the rabbit sera against the heterologous strain 3D7 parasite suggests that this vaccine may be capable of inducing a protective effect against multiple parasite strains.
There are several possible explanations for the differences observed between the immunogenicity and the efficacy of the soluble E. coli MSP1 42 and baculovirus MSP1 42 vaccine candidates. One is that E. coli MSP1 42 may be comprised of noncovalently associated multimers rather than monomers. In support of this, we found that the elution of this antigen from Ni-chelate columns required 1 M imidazole, which has been observed previously for multimeric proteins, while most monomeric proteins bearing hexahistidine tags can be eluted with 100 to 250 mM imidazole (32) . If the induction of protective immunity is dependent on a multimeric Ag, the required effector Ab responses may be directed to quaternary epitopes that are present in the assembled Ag but not the monomeric Ag. A second explanation for the differences is that simple mannosylation at the two N-glycosylation sites on baculovirus MSP1 42 may have altered the antigenicity and reduced the immunogenicity at either the B-cell or T-cell level. Other explanations include the possibilities that subpyrogenic levels of endotoxin present in the E. coli preparation provided for an additional adjuvant effect and that the location of the histidine tag affected the relative antigenicities and immunogenicities of the two vaccines. The His tag which is fused to the N terminus of E. coli MSP1 42 and to the C terminus of baculovirus-MSP1 42 may have altered the T-cell or B-cell responses to vaccination. B-cell epitope mapping by mutagenesis showed that the functionally relevant MAb 12.10 epitope contains critical contact residues located near the C terminus of the protein (40) . Introducing an additional sequence at the C terminus of MSP1 42 of our baculovirus product may have interfered with the induction of immunity to this important epitope. This hypothesis is supported by our observation that E. coli MSP1 42 induced 8.8-fold more Ab specific to EGF-like domain 2 than did baculovirus MSP1 42 and that this Ab response correlated strongly with protection, as measured by the cumulative day 11 parasitemia. Along this line, it should be noted that a strong protective effect was observed in Aotus lemurinus griseimembra vaccinated with baculovirus-expressed MSP1 42 from the FUP strain of P. falciparum and that this Ag was not modified at its C terminus (7) . While these results may suggest that mannosylation did not effect the protection induced by this baculovirus-expressed Ag and may support the idea that it is important to avoid modifying the C-terminal end of MSP1 42 , it is important to consider that, aside from the differences in virulence of the FUP strain in A. nancymai (11) and A. lemurinus griseimembra, Chang et al. gave four immunizations, with each containing a diminishing amount of FCA (7) .
In order to better understand the relationship of the immunity induced by this soluble E. coli-expressed MSP1 42 vaccine and other MSP1 42 vaccine candidates, we analyzed the various trials that were reported previously and were conducted similarly to this trial, i.e., A. nancymai monkeys vaccinated with MSP1 42 (FVO) given with Freund's adjuvant and challenged with erythrocytes infected with P. falciparum strain FVO. Results from previous trials suggested that an inverse relationship exists between occurrences of anemia and self-curing in vaccinated animals, with anemia appearing when there is an unfavorable balance between the immune status and challenge virulence. Given the same challenge, a vaccine that induces the most self-cure outcomes compared to anemia outcomes should be the most potent. The data related to these conclusions are discussed below.
Retrospectively, it appears that the protective effect of our E. coli MSP1 42 vaccine is also stronger than the immunity induced by the baculovirus MSP1 42 vaccine in other comparable trials (36, 37) as well as the immunity induced by secreted transgenic mouse-expressed MSP1 42 (36) or E. coli-expressed, refolded MSP1 42 (35) . All of these trials are summarized in Table 2 . Our conclusion is supported by several observations. First, we compared soluble E. coli-expressed MSP1 42 and baculovirus-expressed MSP1 42 in this present trial after recalculating our primary end points as described previously (37) . A Kruskal-Wallis analysis followed by a Mann-Whitney analysis of these recalculated data showed that the difference in the end points of our soluble E. coli-expressed MSP1 42 vaccine group and the Pvs25 control group was significant at the 95% confidence limit (P ϭ 0.008) but that the difference in the end points of the baculovirus-expressed MSP1 42 vaccine group and the Pvs25 control group was not (P ϭ 0.0947). The weak protective effect of baculovirus-expressed MSP1 42 in the present trial compared with the protective effect observed previously may be due to the administration of two rather than three immunizations and to the difference in the immunization schedules between the two trials. Second, Stowers et al. observed that baculovirus MSP1 42 and NG-transgenic mouseexpressed MSP1 42 were equally potent for inducing protection against a challenge (38) . An important observation from that study is that the self-cure rates after vaccinations with baculovirus MSP1 42 and NG-transgenic mouse-expressed MSP1 42 were higher when control animals were treated for parasitemia between 16 and 18 days after challenge (57%) than when they were treated between 12 and 14 days after challenge (14 to 28%). The converse was true for anemia rates; the anemia rates for both the baculovirus MSP1 42 and the NG-transgenic mouse-expressed MSP1 42 were lower when control animals were treated for parasitemia between 16 and 18 days after challenge (14 to 40%) and were higher when controls were treated between 12 and 14 days after challenge (57%). Thus, trial-to-trial variation in vaccine potency depends on the challenge, and comparisons of trials conducted at different times are best achieved if control animals from those trials are treated for uncontrolled parasitemia within the same time frame after challenge. Third, although a direct comparison was not performed, Singh et al. concluded that refolded E. coliexpressed MSP1 42 (FVO) and baculovirus MSP1 42 are equally potent vaccine candidates (35) . In that experiment, control animals were treated between 11 and 14 days after challenge. The self-cure rate for the refolded E. coli-expressed MSP1 42 (FVO) Ag was 14%, and the anemia rate was 71%, whereas in other studies with the baculovirus Ag tested in equally challenged animals, self-cure and anemia rates were 28 and 56%, respectively (37) . Given that ISA-51 and incomplete Freund's adjuvant are virtually identical formulations, the choice of adjuvant for boosting with refolded E. coli-expressed MSP1 42 (FVO) probably had little effect on the efficacy of this Ag. The soluble E. coli MSP1 42 (FVO) Ag described in the present study seems to be more potent than any of the previous candidates because its associated self-cure (67%) and anemia (33%) rates were the inverse of those observed for other vaccine candidates (14 to 28% and 57 to 72%, respectively) in challenge experiments in which control animals were treated between 11 and 14 days after challenge. The differences between this study and those conducted previously should be reiterated. For this study, animals received two immunizations at 7-week intervals and were challenged 7 weeks after the last immunization with 10,000 PRBC. In previous studies, animals received three immunizations at 3-week intervals and were challenged 2 weeks after the last immunization with 50,000 PRBC. Despite the difference in inoculum sizes used in these studies, all control animals were first treated from 11 to 14 days after challenge ( Table 2 ), indicating that they were challenged equally.
Our results show that MSP1 42 expressed in a soluble form by E. coli and purified according to GMP specifications can induce a very potent protective immune response in A. nancymai when it is coadministered with Freund's adjuvant. Future studies must be directed toward the identification, development, and characterization of adjuvants that will be suitable for human use and that can induce protective immunity, but whether the Aotus monkey represents an appropriate venue for the discovery of such adjuvants remains a point of open debate (19, 39) . 
